Advanced Search

 

Study ID Status Title Patient Level Data
AK1BIOVAIL2526 Completed A pilot, one-period, three-way, cross-over, steady state, open-label, multiple-dose, fasting, comparative bioavailability study of two formulations of bupropion hydrochloride extended release tablets ( 300mg four times daily) versus WELLBUTRIN™ tablets ( 100mg twice daily andthree times daily) in normal healthy non-smoking male volunteers.
AK1BIOVAIL2543 Completed A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300mg extended release tablets (1 X 300mg four times daily) versus WELLBUTRIN 100mg tablets (three times daily) in normal healthy non-smoking male and female subjects
AK1BIOVAIL2544 Completed A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300mg extended release tablets (300mg four times daily) versus Wellbutrin 100mg tablets (three times daily) in normal healthy non-smoking male and female subjects
AK1BIOVAIL2548 Completed A two-way, crossover, open-label, single dose, food-effect, comparative bioavailability study of bupropion HCI extended release 300mg tablets in normal healthy non-smoking male and female subjects
AK1BIOVAIL2571 Completed A two-way, crossover, open-label, single-dose, fasting, dosage strength equivalency study of two strengths (150mg and 300mg) of bupropion HCI extended release tablets given once daily in normal healthy non-smoking male and female subjects
AK1BIOVAIL2572 Completed A two-way, steady state, crossover, open-label, multiple-dose, fasting, comparative bioavailability study of bupropion HCl 30mg extended-release tablets versus Zyban 150mg tablets in normal healthy non-smoking male and female subjects.
AK1BIOVAIL2573 Completed A four-way, crossover, open-label, single-dose, fasting and food effect, comparative bioavailability study of bupropion HCl extended-release 150mg tablets and Zyban 150mg tablets in normal healthy non-smoking male and female subjects
AK1BIOVAIL2594 Completed A four-period, four-treatment, crossover, open-label, single-dose, fasting, in-vitro/in-vivo correlation pharmacokinetic study of three formulations of bupropion HCl extended release 150 mg tablets (fast release, target release and slow release formulations) and bupropion HCl 100 mg oral solution in normal healthy non-smoking male subjects
AKIA401 Completed A single-center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation in heavy smokers (study 401)
ALB110247 Completed Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus Study Listed on ClinicalStudyDataRequest.com
ALKF1001 Completed Report of a Biocomparability Study of Alkeran (melphalan) in Patients with Multiple Myeloma, Ovarian Cancer, Breast Cancer or other solid tumors for which Alkeran has activity.
AMB107816 Completed Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and confirmatory clinical trial>
AMB107818 Completed Study AMB107818, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An open label Study of GSK1325760A to evaluate the Safety and Efficacy of GSK1325760A - a Long-term Extension Study -
AMI02 Completed Phase I study (repeated dose) of sumatriptan intranasal spray.
APV 20003 Completed See Detailed Description
APV10006 Completed A Pivotal, Phase I, Single-dose, Open-label, Randomized, Two-way Crossover Study to Assess the Bioequivalence of 2x700mg GW433908 Oral Film-coated Tablets to 3x465mg GW433908 Oral Film-coated Tablets in Healthy Adult Subjects
APV10007 Completed A Phase I, Single-dose, Open-label, Randomized, Three-way, Balanced, Crossover Study to Assess the Effect of MAALOX TC and ZANTAC on Plasma Amprenavir Pharmacokinetics Following Administration of a 1400mg Single Dose of GW433908
APV10008 Completed A Phase I, Single-dose, Open-label, Randomized, Four-period, Balanced Crossover Study to Assess the Relative Bioavailability of the GW433908 Oral Suspension Relative to the GW433908 Oral Film-coated 700mg Tablet and to Assess the Effects of Food on Amprenavir Pharmacokinetics Following Administr ...
APV10009 Completed A Phase I, Randomized Study to Assess the Effect of Efavirenz 600mg QD on Steady-State Plasma Total Amprenavir and Ritonavir PK Following Coadministration with GW433908 1395mg QD + Ritonavir 200mg QD or GW433908 1395mg QD + Ritonavir 300mg QD for 14 Days as Compared to GW433908 1395mg QD + Riton ...
APV10010 Completed A Phase I, Randomized Study to Assess the Effect of Efavirenz 600mg QD on Steady-State Plasma Total Amprenavir Pharmacokinetics Following Co-administration with GW433908 700mg BID + Ritonavir 100mg BID or GW433908 700mg BID + Ritonavir 200mg BID for 14 Days as Compared to GW433908 700mg BID + RT ...
APV10011 Completed A Phase I, Open, Randomized, Balanced, Incomplete Crossover Drug-Drug Interaction Study to Assess the Steady-State Plasma Amprenavir and Lopinavir Pharmacokinetics following Administration of Lopinavir 533mg/Ritonavir 133mg BID + GW433908 1400mg BID, GW433908 700mg BID + Ritonavir 100mg BID, or…
APV10012 Completed A Phase I, Open, Randomized, Balanced, Incomplete Crossover Drug-Drug Interaction Study to Assess the Steady-State Plasma Amprenavir and Lopinavir Pharmacokinetics following Administration of Lopinavir 400mg/Ritonavir 100mg BID + GW433908 700mg BID + Ritonavir 100mg BID, GW433908 700mg BID + Rit ...
APV10013 Completed A Phase I, Randomized, Open Label, Three Period, Single Sequence, Steady State, Drug-Drug Interaction Study between Atorvastatin 10mg QD and GW433908 1400mg BID and between Atorvastatin 10mg QD and GW433908 700mg BID + Ritonavir 100mg BID in Healthy Adult Subjects
APV10014 Completed A Phase I, Open Label, Single Arm, Three Period, Drug-Drug Interaction Study to Assess the Steady-State Plasma Amprenavir and Nevirapine Pharmacokinetics Following Administration of GW433908 1400mg BID + Nevirapine 200mg BID for 14 days and GW433908 700 mg BID + Nevirapine 200mg BID + Ritonavir ...
APV10015 Completed A Pivotal, Phase I, Single-dose, Open-label, Randomized, Three Period, Balanced Crossover Study to Assess the Bioequivalence of GW433908 Oral Film-coated 700mg Tablet Formulations in Healthy Adult Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.